Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-MASKED STUDY OF THE SAFETY AND EFFICACY OF POS (0.75% PHENTOLAMINE OPHTHALMIC SOLUTION) IN PARTICIPANTS WITH PREVIOUS KERATOREFRACTIVE SURGERY WITH DECREASED VISUAL ACUITY UNDER MESOPIC CONDITIONS

Next Previous
Trial Profile

RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-MASKED STUDY OF THE SAFETY AND EFFICACY OF POS (0.75% PHENTOLAMINE OPHTHALMIC SOLUTION) IN PARTICIPANTS WITH PREVIOUS KERATOREFRACTIVE SURGERY WITH DECREASED VISUAL ACUITY UNDER MESOPIC CONDITIONS

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Phentolamine (Primary)
  • Indications Nyctalopia
  • Focus Registrational; Therapeutic Use
  • Acronyms LYNX-3
  • Sponsors Ocuphire Pharma

Most Recent Events

  • 04 Sep 2025 According to an Opus Genetics media release, LYNX-3 is the second of two, pivotal Phase 3 studies and follows the same study design and patient population as the first study, LYNX-2- for chronic night driving impairment in keratorefractive patients with reduced mesopic vision. These studies have Fast Track designation from the USFDA and are being conducted under a Special Protocol Assessment (SPA).
  • 04 Sep 2025 According to an Opus Genetics media release, 1st patient has been dosed in this trial.
  • 02 Jun 2025 According to an Viatris Pharma media release, this LYNX-3 is anticipated to start shortly with results expected in the first half of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top